-
Mashup Score: 12The 5th Annual OncoAlert Colloquium - 4 month(s) ago
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Source: oncoalert.m-pages.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Emre YekedĂĽz: Happy to share our studies at ASCO GU25 - OncoDaily - 4 month(s) ago
Emre YekedĂĽz: Happy to share our studies at ASCO GU25 / ASCO GU25, ASTRO, cancer, Emre YekedĂĽz, OncoDaily, Oncology, Society of Urologic Oncology
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Happy to share our studies at @ASCO GU25 - @yekeduz_emre https://t.co/m0mLlg319w #Cancer #ASCOGU25 #GUOnc #MedX #MedNews #…
-
-
Mashup Score: 1AI-generated cancer prevention influencers can target risk groups on social media at low cost - 5 month(s) ago
This study explores the potential of Artificial Intelligence (AI)-generated social media influencers to disseminate cancer prevention messages. Utilizing a Generative AI (GenAI) application, we created a virtual persona,
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/yqwbWB7abr
-
-
Mashup Score: 42Toni's Legendary Top 10 Papers List! - 5 month(s) ago
Dr Toni Choueiri, Chief of GU Oncology at Dana-barber Cancer Institute (Boston, USA) returns to GU Cast with members of his team at Dana Farber Cancer Instit…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
We discussed @DrChoueiri 's 2024 #genitourinary #oncology Top10 articles along with my dear colleague @marc_eid hosted by @gu_onc ! (GUCast) Many thanks to @declangmurphy and @RenuEapen for this amazing speed-dating style discussion! https://t.co/MqLMzSfzk8 https://t.co/GBXUNxJjUV
-
-
Mashup Score: 24Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan | Journal of Clinical Oncology - 9 month(s) ago
In April 2024, the US Food and Drug Administration (FDA) granted approval for trastuzumab deruxtecan (T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive (immunohistochemistry [IHC] 3+) solid tumors who have received previous systemic treatment and had no satisfactory alternative treatment options. 1 The tissue-agnostic indication for T-DXd has been authorized under accelerated approval on the basis of objective response rate
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
🌟Insightful comments on HER-2 testing and pan-tumor indication of trastuzumab deruxtecan! @OncoAlert #Oncology #Cancer @DrYukselUrun @dr_yakupergun https://t.co/mx2E9zQ7My
-
-
Mashup Score: 12Immune effects of α and β radionuclides in metastatic prostate cancer - 10 month(s) ago
Nature Reviews Urology – This Review focusses on what is known about the interactions between conventional radiotherapy and the immune system. The authors discuss how this knowledge can be applied…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @APCCC_Lugano: Immune effects of α and β radionuclides in metastatic prostate cancer out on @NatRevUrol https://t.co/TwMqfwHnvm Exter…
-
-
Mashup Score: 12Immune effects of α and β radionuclides in metastatic prostate cancer - 10 month(s) ago
Nature Reviews Urology – This Review focusses on what is known about the interactions between conventional radiotherapy and the immune system. The authors discuss how this knowledge can be applied…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @APCCC_Lugano: Immune effects of α and β radionuclides in metastatic prostate cancer out on @NatRevUrol https://t.co/TwMqfwHnvm Exter…
-
-
Mashup Score: 12Immune effects of α and β radionuclides in metastatic prostate cancer - 10 month(s) ago
Nature Reviews Urology – This Review focusses on what is known about the interactions between conventional radiotherapy and the immune system. The authors discuss how this knowledge can be applied…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @APCCC_Lugano: Immune effects of α and β radionuclides in metastatic prostate cancer out on @NatRevUrol https://t.co/TwMqfwHnvm Exter…
-
-
Mashup Score: 13Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial - 10 month(s) ago
In men with prostate-specific membrane antigen–defined, oligorecurrent M1a–b prostate cancer, short-course androgen annihilation therapy and metastasis-directed stereotactic body radiotherapy achieved a substantial disease-free interval following testosterone recovery. This regimen was well tolerated, and 90% of patients completed therapy with androgen deprivation therapy and at least one androgen receptor pathway inhibitor.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
‼️SBRT+6 mo systemic therapy decreased the recurrence rates in oligorecurrent metastatic prostate cancer! (A phase 2 trial) 🔔 At 6 months after testosterone recovery 50% of all pts were still responder! @OncoAlert @EurUrolOncol @DanaFarber_GU https://t.co/KRry5FOYbo
-
-
Mashup Score: 24Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan | Journal of Clinical Oncology - 10 month(s) ago
In April 2024, the US Food and Drug Administration (FDA) granted approval for trastuzumab deruxtecan (T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive (immunohistochemistry [IHC] 3+) solid tumors who have received previous systemic treatment and had no satisfactory alternative treatment options. 1 The tissue-agnostic indication for T-DXd has been authorized under accelerated approval on the basis of objective response rate
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
🌟Insightful comments on HER-2 testing and pan-tumor indication of trastuzumab deruxtecan! @OncoAlert #Oncology #Cancer @DrYukselUrun @dr_yakupergun https://t.co/mx2E9zQ7My
-
RT @OncoAlert: GI Oncology #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://t.co/Alj0nnUIfA @GillSharlene 🇨🇦 Covering Gastric, Esophag…